The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $428, representing a +0.03% change from its previous close.

Vertex Pharmaceuticals achieved compound earnings per share (EPS) growth of 1.5% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than the ...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller ... It's a milestone after a long history of unsuccessful efforts to develop painkillers without the ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

On Thursday, the Food and Drug Administration approved the non-opioid pain relievers from Vertex Pharmaceuticals, a new ...

Vertex Pharmaceuticals could be on the cusp of ... GPU platform could become the most successful product in its history. Huang even thinks Blackwell could become the most successful product ...